Tiotropium mist (Respimat) increases mortality risk, authors say

Singh et al analyzed 5 randomized trials comparing tiotropium mist to placebo, and found a 46% relative increased risk of all-cause mortality among the treated arms. The Respimat inhaler is available in Europe, but the FDA has not approved it in the US. BMJ 2011;342:d3215.